GREAT SCIENCE. GREAT MEDICINE.
BATTLING SERIOUS DISEASE.

Human Genome Sciences exists to place new therapies into the hands of those battling serious disease.

First HGS Product to Receive Regulatory Approval

On March 9, 2011, HGS and GlaxoSmithKline PLC (GSK) announced FDA approval of BENLYSTA® (belimumab) for the treatment of autoantibody-positive adult patients with active, systemic lupus erythematosus who are receiving standard therapy. BENLYSTA is the first new approved drug for lupus in more than 50 years – and the first HGS product to receive FDA approval.

Products in Late-Stage Development

We achieved our first product sales in 2009 by delivering 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalation anthrax. We secured a new purchase order in July 2009 for 45,000 doses of raxibacumab to be delivered over a three-year period. We expect to receive approximately $142 million from this second award as deliveries are completed, including $65 million received through December 31, 2010.

We also have substantial financial rights to certain products in the GSK clinical pipeline. GSK is currently conducting Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease and albiglutide in patients with type 2 diabetes mellitus.

Emerging Mid-Stage Pipeline

Right behind these late-stage products is an emerging mid-stage pipeline, led by our oncology program and potential additional indications for BENLYSTA.

At HGS, we are committed to improving the lives of patients – and to achieving commercial success and sustainable growth well into the future.